Clinical landscape of LAG-3-targeted therapy

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Lymphocyte-activated gene 3 (LAG-3) is an inhibitory immune receptor regulating T-cell function and immune homeostasis.
• LAG-3 is emerging as a key immune checkpoint, comparable to PD-1 and CTLA-4, for cancer immunotherapy.
• It represents the third inhibitory receptor targeted in human anticancer therapies.

Purpose of the Study:

• To identify and classify preclinical and clinical trials involving LAG-3 as a therapeutic target.
• To summarize current understanding of LAG-3 clinical applications.
• To review and discuss available data on LAG-3-targeted therapy development.

Main Methods:

• Extensive bibliographic research to identify relevant trials.
• Classification of preclinical and clinical studies.
• Review and synthesis of publicly available data.

Main Results:

• Several LAG-3-antagonistic immunotherapies are in preclinical and clinical development.
• Combination therapies, particularly LAG-3 with PD-1 blockade, show encouraging results.
• Bispecific PD-1/LAG-3 agents effectively target dysfunctional T cells, enhancing their activity.

Conclusions:

• LAG-3 is a significant target in the development of novel cancer immunotherapies.
• Co-blockade strategies and bispecific agents represent promising advancements.
• Further research and clinical evaluation are ongoing for LAG-3-targeted therapies.